[Direct comparison of endothelial and metabolic effects of perindopril combination with indapamide retard or hydrochlorothiazide]
Related Experiment Video
Updated: Apr 14, 2026

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
Published on: May 17, 2024
Insights
Perindopril combined with indapamide retard showed better vascular and metabolic improvements in hypertensive patients than hydrochlorothiazide, despite similar blood pressure reduction. This suggests a potentially better long-term prognosis with indapamide retard.
Area of Science:
- Cardiology
- Pharmacology
- Metabolic Health
Background:
- Essential hypertension management requires effective blood pressure control.
- Combination therapies are often used to achieve target blood pressure.
- Assessing vascular and metabolic effects of different antihypertensive drug combinations is crucial for long-term patient outcomes.
Purpose of the Study:
- To compare vascular and metabolic parameter changes in patients with essential hypertension.
- To evaluate the effects of perindopril combined with either indapamide retard or hydrochlorothiazide.
Main Methods:
- 40 hypertensive patients were randomized to perindopril plus indapamide retard (P+I) or perindopril plus hydrochlorothiazide (P+HT).
- Vascular parameters (endothelial function, arterial stiffness) and metabolic parameters (lipids, glucose) were assessed at baseline and 6 months.
- Photoplethysmography was used to measure vascular responses.
Main Results:
- Both combinations achieved similar blood pressure reduction.
- Perindopril plus hydrochlorothiazide significantly worsened endothelial function, triglycerides, and glucose levels.
- Perindopril plus indapamide retard was metabolically neutral and showed a trend towards greater improvement in arterial stiffness.
Conclusions:
- Perindopril combined with indapamide retard offers superior vascular and metabolic benefits compared to hydrochlorothiazide in hypertensive patients.
- These findings suggest a potentially better long-term prognosis with the perindopril-indapamide retard combination.
Objective:
Our aim was to compare changes of vascular and metabolic parameters in patients with essential hypertension on treatment with combination of perindopril with either indapamide retard or hydrochlorothiazide.
Methods:
The study involved 40 patients who were randomly assigned to perindopril 5-10 mg/day in combination with indapamide retard (P+I) 1.5 mg/day (n = 20) or with hydrochlorothiazide (P+HT) 25 mg/day (n=20). Waist circumference, body mass index, blood lipids and glucose, endothelial function (EF) determined as the change of resistance index after inhalation of salbutamol, arterial stiffness measured as mean pulse wave velocity after sublingual trinitroglycerin (PWVtng) were evaluated at baseline and 6 months thereafter. Vascular responses were calculated from digital pulse waves registered using photoplethysmography.
Results:
Dynamics of BP after 6 months did not differ significantly between groups. Treatment with combination of P+HT resulted in significant decrease of EF (-24,3%, p<0,05) accompanied by negative changes of triglycerides (+13,4%, p<0,05) and glucose levels (+9,8%, p<0,05), whereas combination of P+I did not affect endothelial function and was metabolically neutral. PWVtng significantly decreases on both regiments of treatment with the trend in favor of P+I combination (-13,4%, p<0,001 versus -9,8%, p<0,01 for P+I and P+HT combinations, respectively).
Conclusion:
Thus, despite the similar BP reduction the combination of ACE-inhibitor--perindopril with indapamide retard possesses more favorable vascular and metabolic effects compared to combination with hydrochlorothiazide that potentially may account for different prognosis of patients with arterial hypertension on long-term treatment.
Related Concept Videos
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Thiazide-Class Diuretics
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure V: Medical Management
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

